INTRODUCTION

DAPAMECH:

This is a series of mechanistic trials that will continue to advance our understanding of the underlying science behind the CV and renal effects of dapagliflozin.

THE DAPAMECH

HF disease-specific biomarkers, symptoms, health status, and QoL in patients with T2D and chronic HF with reduced systolic function

“Click to view”

View More

HF disease-specific biomarkers, symptoms, health status, and QoL in patients with T2D or prediabetes and chronic HF with preserved systolic function

“Click to view”

View More

The natriuretic effect in patients with T2D with preserved or impaired renal function and ND patients with impaired renal function

“Click to view”

View More

Insulin sensitivity in skeletal muscle in patients with T2D taking no diabetes medication or metformin only

“Click to view”

View More

Cardiac substrate uptake, myocardial efficiency and myocardial contractile work in patients with T2D

“Click to view”

View More

The renoprotective effects in nondiabetic patients with proteinuria and on stable dose of ACEi or ARB

“Click to view”

View More

DISCLAIMER

The effects listed above are not included in the indications for dapagliflozin. Please consult your local prescribing information for the approved use of dapagliflozin. 

For full prescribing information, kindly refer to the approved package insert

S4 FORXIGA® 5 mg (tablets) Reg. No. 46/21.2/0214. Each tablet contains the equivalent of 5 mg dapagliflozin as dapagliflozin propanediol. Contains lactose anhydrous.
S4 FORXIGA® 10 mg (tablets) Reg. No. 46/21.2/0215. Each tablet contains the equivalent of 10 mg dapagliflozin as dapagliflozin propanediol. Contains lactose anhydrous.
PHARMACOLOGICAL CLASSIFICATION:A 21.2 Oral hypoglycaemics. INDICATIONS: FORXIGA ® is indicated in adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control as monotherapy or add-on combination therapy. WARNINGS AND PRECAUTIONS: Reports of metabolic acidosis, including ketoacidosis, which were serious life-threatening or fatal, in patients taking FORXIGA ®. Patients who present with signs and symptoms, should discontinue FORXIGA® and the patient should be promptly evaluated and managed accordingly

AstraZeneca Pharmaceuticals (Pty) Ltd. South Africa Reg. No. 1992/005854/07

Building 2, Northdowns Office Park, 17 Georgian Crescent West, Bryanston, 2191, South Africa.
Private Bag X23, Bryanston, 2021, South Africa.
Tel: 011 797-6000. Fax: 011 797-6001. www.astrazeneca.co.za.

Activity ID: ZA-1590. Expiry Date: October 2020
Legal Notice and Terms of Use | Cookies | Privacy Notice | References


Social media, review sites and other public internet sites are not the places for your comments and questions, however questions or comments can be answered by the AZ Medical Information Service at the following addresses: South African markets: SA.MEAMedinfo@astrazeneca.com
or call: 011-797 6000

For adverse event reporting please visit http://aereporting.astrazeneca.com

astrazeneca